Media headlines about Beigene (NASDAQ:BGNE) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Beigene earned a news sentiment score of 0.23 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.7830442624343 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

Shares of Beigene (NASDAQ BGNE) opened at $125.48 on Friday. The stock has a market cap of $6,624.47, a P/E ratio of -96.52 and a beta of 0.61. Beigene has a 1 year low of $34.36 and a 1 year high of $142.00. The company has a current ratio of 9.33, a quick ratio of 9.27 and a debt-to-equity ratio of 0.20.

Beigene (NASDAQ:BGNE) last posted its earnings results on Monday, November 13th. The company reported $2.54 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.23 by $2.31. The business had revenue of $220.21 million for the quarter, compared to analyst estimates of $1.55 million. During the same period last year, the company posted ($1.08) EPS. analysts expect that Beigene will post -2.04 earnings per share for the current year.

A number of research firms have recently commented on BGNE. Robert W. Baird reaffirmed a “neutral” rating and set a $83.00 price objective (up previously from $58.00) on shares of Beigene in a research note on Tuesday, November 14th. Maxim Group set a $120.00 price objective on shares of Beigene and gave the company a “buy” rating in a research note on Monday, January 22nd. Zacks Investment Research downgraded shares of Beigene from a “hold” rating to a “sell” rating in a research report on Monday, November 13th. Cowen reissued a “buy” rating on shares of Beigene in a research report on Monday, January 8th. Finally, ValuEngine raised shares of Beigene from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Beigene has an average rating of “Buy” and an average price target of $96.67.

In other Beigene news, CEO John Oyler sold 20,137 shares of the company’s stock in a transaction that occurred on Tuesday, December 26th. The stock was sold at an average price of $96.46, for a total value of $1,942,415.02. Following the completion of the transaction, the chief executive officer now owns 110,179 shares in the company, valued at approximately $10,627,866.34. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bros. Advisors Lp Baker purchased 1,980,198 shares of the firm’s stock in a transaction on Thursday, January 18th. The stock was bought at an average price of $101.00 per share, with a total value of $199,999,998.00. The disclosure for this purchase can be found here. In the last three months, insiders have sold 483,482 shares of company stock valued at $42,139,474. Corporate insiders own 19.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Beigene (BGNE) Earns Coverage Optimism Score of 0.23” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://theolympiareport.com/2018/02/11/beigene-bgne-earns-coverage-optimism-score-of-0-23.html.

Beigene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.